Navigation Links
A new measure for the malignancy of melanoma
Date:3/12/2009

Every tumor, starting from a size of a few millimeters, depends on a supply of nutrients and oxygen. Therefore, using special growth factors, it induces vascular wall cells of neighboring blood vessels to sprout new capillaries in order to get connected to the blood circulation.

This process called angiogenesis involves a number of different growth factors and their respective receptors on the vascular wall cells. The departments of Prof. Dr. Hellmut Augustin and Prof. Dirk Schadendorf of DKFZ and Mannheim Medical Faculty of the University of Heidelberg have investigated the role of a growth factor called angiopoietin-2 (Ang2) in malignant melanoma. The docking station of Ang2 is the receptor Tie2 on the surface of endothelial cells, which form the inner lining of blood vessels. Together with other signaling molecules, Ang2 induces sprouting of endothelial cells and the formation of new capillaries.

When measuring the Ang2 concentrations in blood samples of melanoma patients, the investigators discovered that larger tumors and more advanced disease stages correlate with high levels of Ang2. If one tracks the Ang2 levels of individual patients over time, a rise parallel to disease progression can be observed. In contrast, patients who have lived with the disease for a long time, i.e., whose disease is not or only slightly progressive, have lower Ang2 levels. The scientists found out that Ang2 concentration in blood serum is a more precise indicator of the progression and stage of the disease than previously used biomarkers.

This close association between melanoma progression and Ang2 level prompted the question of whether the Ang2 growth factor really only stimulates vascularization in the tumor or whether it has additional influence on the properties of the cancer cells themselves. Such an effect had not yet been proposed for any one of the various growth factors which act on the cells of the vascular walls. Melanoma cells were really found to produce both soluble Ang2 and the matching receptor, Tie2, on their own cell membrane. As a result, they are theoretically capable of activating themselves. In order to check this, researchers switched off the Ang2 production in melanoma cells using a genetic trick. Test systems in the culture dish subsequently revealed that the skin cancer cells had lost their ability to migrate. The migration tendency of cancer cells is regarded as important information about their ability to invade other tissue in the body and metastasize.

The tumor appears to seize the signaling system of vascularization and, thus, to strengthen its malignant properties. "Ang2 is a very promising candidate," Hellmut Augustin comments on the results, both as a biomarker for better monitoring of disease progression and as a target structure for therapy measures." Blocking Ang2 might not only attack the tumor's blood supply, but also reduce its malignant growth.


'/>"/>

Contact: Dr. Sibylle Kohlstdt
s.kohlstaedt@dkfz.de
Helmholtz Association of German Research Centres
Source:Eurekalert

Related medicine news :

1. Neck Fat a Measure of Heart Risk
2. Study tests reliability of more accurate measure of patient pain
3. BurrellesLuce VP Johna Burke to Be Featured Presenter For PRSA's March 9th Free Webinar on 'Smart Measurement'
4. Computer-aided system effectively detects and measures pneumothoraces in chest trauma patients
5. New findings measure precise impact of fat on cancer spread
6. Study Shows Simple Measures May Help Prevent Sudden Death Event in Young Athletes
7. LENA Foundation Technology Measures Effectiveness of Autism Therapy
8. BurrellesLuce VP Johna Burke Among Measurement Experts To Speak at Feb. 25 Meeting of PRSA's National Capital Chapter
9. Should intra-abdominal pressure measurement be a routine for all pancreatitis patients?
10. URAC Calls for Public Comment on Revisions to its Pharmacy Benefit Management (PBM) and Drug Therapy Management (DTM), Version 2.0 Standards and NEW Performance Measures, and PHARM Core, Version 3.0 Standards
11. Efficacy of stents is improved when their placement is determined by arterial blood flow measurement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... rough waters, but it continues to present great opportunities ... featured companies for today: Intrexon Corp. (NYSE: ... ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... Learn more about these stocks and receive your complimentary ...
Breaking Medicine Technology: